| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.07 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.079 | 0.08 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.053 | 0.08 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.29 | 0.08 |
| mRNA | selumetinib:vorinostat (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |